Jocelyn Solis-Moreira

Feature Writer

B.Sc. Integrative Neuroscience, M.Sc. Psychology

Jocelyn Solis-Moreira graduated with a Bachelor's in Integrative Neuroscience, where she then pursued graduate research looking at the long-term effects of adolescent binge drinking on the brain's neurochemistry in adulthood. She is adept at translating and summarizing complex study findings in all medical fields with a particular interest in neurodegenerative diseases, cancer research, infectious diseases, and public health. As a freelance writer, her work spans from news articles and feature articles to evergreen explainers across many publications. Her overall goal is to make science accessible for all.

Articles from Jocelyn

High seroprevalence in Peruvian population recovering from SARS-CoV-2 infection

By the middle of 2020, Iquitos, Peru, had the highest number of SARS-CoV-2 antibodies in the world. Despite natural immunity, the city experienced a second coronavirus wave, with reinfections possibly owing to the P.1 variant.

22 May 2021

Resuming global childhood vaccination campaigns during the COVID-19 pandemic

New research published on the medRxiv* preprint server suggests childhood vaccination to prevent other infectious diseases has plummeted during the pandemic. The decrease appears to stem from the suspension of health campaigns promoting immunization and the risk of catching the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

20 May 2021

COVID-19 cases in summer 2020 was not as low as previously thought, new genome-based model suggests

Many have attributed the low number of coronavirus disease 2019 (COVID-19) cases in the summer of 2020 to hot weather or increased outdoor activities. But a new study from researchers in Germany suggests this might not have been the case.

20 May 2021

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

New research published on the preprint server bioRxiv* performed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic simulations to understand the evolutionary transition from a bat-adapted SARS-CoV-2 to a human-adapted virus.

19 May 2021

Study identifies mechanism behind SARS-CoV-2 fusion of host cells

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mediated by the fusion of the spike protein to nearby healthy cells. New research by German researchers sheds light on how this happens.

19 May 2021

SpaceX study profiles evolution of antibody response during COVID-19 infection

New research published on the preprint server bioRxiv* suggests S2-specific antibody responses are critical in recovering from mild to severe COVID-19 infection. Compared to patients who died within 28 days of their COVID-19 diagnosis, patients who produced a wide range of S2-specific responses were more likely to survive.

18 May 2021

COVID-19 public health interventions reduced other respiratory infections

Wearing masks and quarantining while sick has helped mitigate the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An indirect benefit of these efforts appears to be a decrease in flu cases and other respiratory infections. New research led by Lisa G. Winston of the University of California, San Francisco, confirmed COVID-19 public health interventions helped decrease the number of airborne viruses.

18 May 2021

Around half of U.S. parents unwilling to vaccinate their children against COVID-19

A national online survey in March 2021 found only 49.4% of parents living in the United States were planning to vaccinate their child. A parents’ vaccination status and level of vaccine hesitancy were associated with adolescent vaccinations against COVID-19.

18 May 2021

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults

Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.

16 May 2021

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

The World Health Organization (WHO) has labeled the double mutant B.1.617 variant — first discovered in India —a variant of concern for its high transmission rate and ability to evade immune responses. New research posted to the preprint server bioRxiv finds B.1.617 can modestly reduce neutralizing antibody responses generated from the Pfizer-BioNTech vaccine.

16 May 2021